Subgroup analyses found that SGLT-2 inhibitors were more effective than the control groups and DPP-4 inhibitors in lowering AKI events in patients with CVD, CKD, and ACEi/ARB treatment. This evidence concerns the gene DPP4 and chronic kidney disease.